Abstract
This chapter discusses the oxamniquine. Oxamniquine became available in 1975 for the treatment of the tropical disease schistosomiasis, a parasitic worm infection of man. Oxamniquine is a metabolite of the most active of a novel series of 2-aminomethyltetrahydroquinoline compounds that showed promising schistosomicidal activity and low toxicity in laboratory animals. The drug is effective in all stages of the infection and in patients with hepatosplenic involvement. It causes worms to shift from the mesenteric veins to the liver where they are destroyed. The primary mechanism of action of oxamniquine in unknown, even though the drug exhibits anticholinergic properties. It is a light orange crystalline powder. Its melting point is 151° to 152°C. Its pale yellow crystals are obtained from isopropanol.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
